Guinea

thelancet.com - Michael Edelstein, Philip Angelides, David L Heymann - February 8, 2015
DOI: http://dx.doi.org/10.1016/S0140-6736(15)60203-3

The resurgence of polio in Syria in 2013 has shown how a breakdown in public health can lead to the re-emergence of previously well-controlled diseases. In 2014 and early 2015 Liberia, Guinea, and Sierra Leone have focused all resources on the Ebola response at the expense of other health programmes. Combined with losing a large proportion of the health-care workforce and the population's reluctance to attend health-care facilities for fear of Ebola, this means the three countries are now at increased risk of other diseases that their health programmes usually target.

(READ COMPLETE ARTICLE) 

REUTERS                                                                                                          March 16, 2015

LONDON  - Scientists are to test a new two-shot Ebola vaccine using an experimental shot from Britain's GlaxoSmithKline, which is already in clinical trials in Africa, and a new kind of booster from Emergent BioSolutions.

A health worker, left, injects a man in his arm with an Ebola vaccine in Conakry, Guinea, March 7, 2015. The World Health Organization is starting large-scale testing of an experimental Ebola vaccine in Guinea  to see how effective it might be in preventing future outbreaks of the deadly virus.  (AP Photo/ Youssouf Bah)

The Maryland-based biotech company said on Monday its modified vaccinia Ankara (MVA) Ebola Zaire vaccine would be used in an initial Phase I clinical study to be conducted by researchers at the University of Oxford.

Although Ebola case numbers have fallen to a low level, drug companies are still pushing ahead with efforts to develop an effective vaccine, which may help fight the next outbreak, even if it does not come in time for the current epidemic.

QUARTZ  by Grace Dobush                                         March 13, 2015

AUSTIN, Texas—Perhaps the most surprising and important product debuting at SXSW Interactive this year is a personal protective equipment (PPE) prototype for health care workers dealing with Ebola, a tangible result of the U.S. government adapting the culture of innovation and design thinking so key in the startup world.

A team from the U.S. Agency for International Development demonstrated the traditional Ebola suit and the new suit in a preview for Quartz....

TIME MAGAZINE  by Alexandra Sifferlin                                                                        March 13, 2015

The National Institutes of Health (NIH) may relocate its clinical trials of Ebola vaccines to Guinea, since there are no longer enough Ebola cases in Liberia for a proper efficacy trial.

On Feb. 2, the NIH launched an initial safety trial for two vaccines to protect against Ebola in Liberia. The plan was to test 600 people for overall safety and then launch a second phase of the trial in 27,000 people to see whether or not the vaccine prevents infection with Ebola virus compared to a placebo.

The safety test was successfully completed the week of March 9—but around the same time, Liberia announced that it had released its last confirmed patient from its Ebola treatment centers. ...